Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity | Zendy

Laura N. Walti | Zendy; Julia Steinrücken | Zendy; Andri Rauch | Zendy; Gilles Wandeler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity

Author(s) -

Laura N. Walti,

Julia Steinrücken,

Andri Rauch,

Gilles Wandeler

Publication year - 2018

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofy275

Subject(s) - tenofovir alafenamide , medicine , nephrotoxicity , renal function , tenofovir , cobicistat , prodrug , proteinuria , human immunodeficiency virus (hiv) , toxicity , emtricitabine , pharmacology , kidney , antiretroviral therapy , virology , viral load

Although the use of tenofovir alafenamide (TAF), a new prodrug of tenofovir, was safe and efficacious in clinical trials, real-world data from multimorbid individuals are scarce. Among 10 persons living with HIV with previous tenofovir disoproxil fumarate-induced nephrotoxicity, renal function remained stable, and proteinuria decreased in several patients after the switch to TAF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research